Please login to the form below

Not currently logged in
Email:
Password:

V Bryan Lawlis joins board of KaloBios

Is co-founder of Itero and Covance

KaloBios has announced that Dr V Bryan Lawlis is to join the company's board of directors.

Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

He has entrepreneurial experience, co-founding Itero in 2006 and contract manufacturing firm Covance Biotechnology Services in 1996.

Other previous roles include CEO of Aradigm Corporation, VP of process sciences at Genetech.

His extensive industry knowledge and drug development experience, especially in the manufacturing of therapeutic proteins and antibodies, will serve KaloBios well as we advance the development of our portfolio of proprietary, patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios.

This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

9th August 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...